Diphtheria, tetanus, pertussis (acellular, component) hepatitis B (rDNA), polioimyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed).
One dose1 (0.5-ml) contains: Diphtheria Toxoid not less than 20 IU2; Tetanus Toxoid not less than 40 IU2; Bordetella pertusis antigens: Pertussis Toxoid 25 micrograms, Filamentous Haemagglutinin 25 micrograms; Poliovirus (Inactivated)3: Type 1 (Mahoney) 40 D antigen units4, Type 2 (MEF-1) 8 D antigen units4, Type 3 (Saukett) 32 D antigen units4; Hepatitis B surface antigen5 10 micrograms; Haemophilus influenzae type b polysaccharide 12 micrograms; (Polyribosylribitol Phosphate) conjugated to Tetanus protein 22-36 micrograms.
1Adsorbed on aluminum hydroxide, hydrated (0.6 mg Al3+).
2As lower confidence limit (p=0.95).
3Produced on Vero cells.
4Or equivalent antigenic quantity determined by a suitable immunochemical method.
5Produced in yeast Hansenula polymorpha cells by recombinant DNA technology.
The vaccine may contain traces of glutaraldehyde, formaldehyde, neomycin, streptomycin and polymixin B which are used during the manufacturing process (see Contraindications).
Excipients/Inactive Ingredients: Disodium hydrogen phosphate, Potassium dihydrogen phosphate, Trometamol, Saccharose, Essential amino acids including L-phenylalanine, Water for injection.
Vaccines, Bacterial and viral vaccines combined. ATC code:
The priming vaccination schedules that have been used are: 6, 10, 14 weeks with and without hepatitis B vaccination at birth; 2, 4, 6 months with and without hepatitis B vaccination at birth.
Results obtained for each of the components are summarised in the tables as follows (see Table 1 and Table 2.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Vaccine efficacy of the acellular pertussis (aP) antigens contained in Hexaxim against the most severe WHO-defined typical pertussis (≥21 days of paroxysmal cough) is documented in a randomised double-blind study among infants with a 3 dose primary series using a DTaP vaccine in a highly endemic country (Senegal). The need for a toddler booster dose was seen in this study.
The long-term capability of the acellular pertussis (aP) antigens contained in Hexaxim to reduce pertussis incidence and control pertussis disease in the childhood has been demonstrated in a 10-year national pertussis surveillance on pertussis disease in Sweden with the pentavalent DTaP-IPV/Hib vaccine using a 3, 5, 12 months schedule. Results of long term follow-up demonstrated a dramatic reduction of the pertussis incidence following the second dose regardless of the vaccine used.
The vaccine effectiveness against Hib invasive disease of DTaP and Hib combination vaccines (pentavalent and hexavalent including vaccines containing the Hib antigen from Hexaxim) has been demonstrated in Germany via an extensive (over five years follow-up period) post-marketing surveillance study. The vaccine effectiveness was of 96.7% for the full primary series, and 98.5% for booster dose (irrespective of priming).
No pharmacokinetic studies have been performed.
Toxicology: Preclinical Safety Data:
Nonclinical data revealed no special hazard for humans based on conventional repeat dose toxicity and local tolerance studies.
At the injection sites, chronic histological inflammatory changes were observed, that are expected to have a slow recovery.
Hexaxim (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).
The use of Hexaxim should be in accordance with official recommendations.
Primary Vaccination: The primary vaccination consists of three doses of 0.5 mL to be administered at intervals of at least four weeks and as per schedule 6, 10, 14 weeks and 2, 4, 6 months.
All vaccination schedules including the WHO Expanded Program on Immunisation (EPI) at 6, 10, 14 weeks can be used whether or not a dose of hepatitis B vaccine has been given at birth.
Where a dose of hepatitis B vaccine is given at birth, Hexaxim can be used for supplementary doses of hepatitis B vaccine from the age of six weeks. If a second dose of hepatitis B vaccine is required before this age, monovalent hepatitis B vaccine should be used.
The use of this vaccine should be in accordance with official recommendations.
Booster Vaccination: After a 3-dose primary vaccination with Hexaxim (6, 10, 14 weeks and 2, 4, 6 months), a booster dose of HepB and Hib must be administered during the second year of life and at least 6 months after the last priming dose.
Booster doses should be given in accordance with the official recommendations. At the very least, a dose of Hib vaccine must be administered.
After a 3-dose WHO EPI schedule with Hexaxim (6, 10, 14 weeks) and in the absence of hepatitis B vaccination at birth, a hepatitis B vaccine booster must be given. At the very least, a booster dose of polio vaccine should be given. Hexaxim can be considered for the booster.
When a hepatitis B vaccine is given at birth, after a 3-dose primary vaccination, Hexaxim or a pentavalent DTaP/IPV/Hib vaccine can be administered for the booster.
Hexaxim may be used as a booster in individuals who have previously been vaccinated with another hexavalent vaccine or pentavalent DTaP-IPV/Hib vaccine associated with a monovalent hepatitis B vaccine.
Other pediatric population: The safety and efficacy of Hexaxim in children over 24 months of age have not been established.
Method of Administration: Immunisation must be carried out by intramuscular (IM) injection. The recommended injection site is preferably the antero-lateral area of the upper thigh and the deltoid muscle in older children (possibly from 15 months of age).
No cases of overdose have been reported.
History of an anaphylactic reaction after a previous administration of Hexaxim.
Hypersensitivity to the active substances, to any of the excipients listed in Description, to trace residuals (glutaraldehyde, formaldehyde, neomycin, streptomycin and polymyxin B), to any pertussis vaccine, or after previous administration of Hexaxim or a vaccine containing the same components or constituents.
Vaccination with Hexaxim is contraindicated if the individual has experienced an encephalopathy of unknown aetiology, occurring within 7 days following prior vaccination with a pertussis containing vaccine (whole cell or acellular pertussis vaccines).
In these circumstances, pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria, tetanus, hepatitis B, poliomyelitis and Hib vaccines.
Pertussis vaccine should not be administered to individuals with uncontrolled neurologic disorder or uncontrolled epilepsy until treatment for the condition has been established, the condition has stabilized and the benefit clearly outweighs the risk.
Hexaxim will not prevent disease caused by pathogens other than Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, hepatitis B virus, poliovirus or Haemophilus influenzae type b. However, it can be expected that hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
Hexaxim will not protect against hepatitis infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E or by other liver pathogens.
Because of the long incubation period of hepatitis B, it is possible for unrecognized hepatitis B infection to be present at the time of vaccination. The vaccine may not prevent hepatitis B infection in such cases.
Hexaxim does not protect against infectious diseases caused by other types of Haemophilus influenzae or against meningitis of other origins.
Prior to Immunization: Immunisation should be postponed in individuals suffering from moderate to severe acute febrile illness or infection. The presence of a minor infection and/or low-grade fever should not result in the deferral of vaccination.
Vaccination should be preceded by a review of the person's medical history (in particular, previous vaccinations and possible adverse reactions). The administration of Hexaxim must be carefully considered in individuals who have a history of serious or severe reaction within 48 hours following administration of vaccine containing similar components.
Before the injection of any biological, the person responsible for administration must take all precautions known for the prevention of allergic or any other reactions. As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following administration of the vaccine.
If any of the following events are known to have occurred after receiving any pertussis containing vaccine, the decision to give further doses of pertussis containing vaccine should be carefully considered: Temperature of ≥40°C within 48 hours not due to another identifiable cause; Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination; Persistent, inconsolable crying lasting ≥3 hours, occurring within 48 hours of vaccination; Convulsions with or without fever, occurring within 3 days of vaccination. There may be some circumstances such as high incidence of pertussis, when the potential benefits outweigh possible risks.
A history of febrile convulsions, a family history of convulsions or Sudden Infant Death Syndrome (SIDS) do not constitute a contraindication for the use of Hexaxim. Individuals with a history of febrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days post vaccination.
If Guillain-Barre syndrome or brachial neuritis has occurred following receipt of prior vaccine containing tetanus toxoid, the decision to give any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks, such as whether or not the primary vaccination has been completed. Vaccination is usually justified for individuals whose primary vaccination is incomplete (i.e. fewer than three doses have been received).
The immunogenicity of the vaccine may be reduced by immunosuppressive treatment or immunodeficiency. It is recommended to postpone vaccination until the end of such treatment or disease. Nevertheless, vaccination of subjects with chronic immunodeficiency such as HIV infection is recommended even if the antibody response may be limited.
Special Populations: No data are available for premature infants. However, a lower immune response may be observed and the level of clinical protection is unknown.
Immune responses to the vaccine have not been studied in the context of genetic polymorphism.
In individuals with chronic renal failure, an impaired hepatitis B response is observed and administration of additional doses of hepatitis B vaccine should be considered according to the antibody level against hepatitis B virus surface antigen (anti-HBsAg).
Precautions for use: Do not administer by intravascular, intradermal or subcutaneous injection.
As with all injectable vaccines, the vaccine must be administered with caution to individuals with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration.
The potential risk of apnoea and the need for respiratory monitoring for 48 to 72 hours should be considered when administering the primary immunisation series to very premature infants (born ≤28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.
Interference with Laboratory Testing: Since the Hib capsular polysaccharide antigen is excreted in the urine, a positive urine test can be observed within 1 to 2 weeks following vaccination. Other tests should be performed in order to confirm Hib infection during this period.
Effects on ability to drive and use machines: Not applicable.
Not applicable. This vaccine is not intended for administration to women of child-bearing age.
Summary of the safety profile:
In clinical studies in individuals who received Hexaxim, the most frequently reported reactions include injection-site pain, irritability, crying, and injection-site erythema.
Slightly higher solicited reactogenicity was observed after the first dose compared to subsequent doses.
Tabulated list of adverse reactions:
The following convention has been used for the classification of adverse reactions: Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000); Not known (cannot be estimated from available data). (See Table 3.)
Click on icon to see table/diagram/image
Description of selected adverse reactions:
Extensive limb swelling: Large injection-site reaction (>50 mm), including extensive limb swelling from the injection site beyond one or both joints, have been reported in children. These reactions start within 24-72 hours after vaccination, may be associated with erythema, warmth, tenderness or pain at the injection site and resolve spontaneously within 3-5 days. The risk appears to be dependent on the number of prior doses of acellular pertussis containing vaccine, with a greater risk following the 4th and 5th doses.
Potential adverse events:
(i.e. adverse events which have been reported with other vaccines containing one or more of the components or constitutents of Hexaxim and not directly with Hexaxim).
Immune system disorders:
Nervous system disorders:
Convulsion with or without fever; Brachial neuritis and Guillain-Barre Syndrome have been reported after administration of a tetanus-toxoid containing vaccine; Peripheral neuropathy (polyradiculoneuritis, facial paralysis), optic neuritis, central nervous system demyelination (multiple sclerosis) have been reported after administration of a hepatitis B antigen containing vaccine; encephalopathy/encephalitis.
Respiratory, thoracic and mediastinal disorders:
Apnoea in very premature infants (≤28 weeks of gestation) (see Precautions).
General disorders and administration site conditions:
Oedematous reaction affecting one or both lower limbs may occur following vaccination with Haemophilus influenzae
type b containing vaccines. If this reaction occurs, it is mainly after primary injections and within the first few hours following vaccination. Associated symptoms may include cyanosis, redness, transient purpura and severe crying. All events should resolve spontaneously without sequel within 24 hours.
Data on concomitant administration of Hexaxim with a pneumococcal polysaccharide conjugated vaccine have shown no clinically relevant interference in the antibody response to each of the antigens.
Data on concomitant administration of a booster dose of Hexaxim with measles-mumps-rubella vaccines have shown no clinically relevant interference in the antibody response to each of the antigens. There may be a clinically relevant interference in the antibody response of Hexaxim and a varicella vaccine and these vaccines should not be administered at the same time.
Data on concomitant administration of rotavirus vaccines have shown no clinically relevant interference in the antibody response to each of the antigens.
No data are available on concomitant administration of Hexaxim with meningococcal vaccines.
If co-administration with another vaccine is considered, immunisation should be carried out on separate injection sites.
Hexaxim must not be mixed with any other vaccines or other parenterally administered medicinal products.
Except in the case of immunosuppressive therapy (see Precautions), no significant clinical interaction with other treatments or biological products has been reported.
Interference with laboratory testing: see Precautions.
Special precautions for disposal and other handling: Prior to administration, the pre-filled syringe should be shaken in order to obtain a homogeneous, whitish, cloudy suspension.
Incompatibility: In the absence of compatibility studies, this vaccine must not be mixed with other vaccines or medicinal products.
Store in a refrigerator (2°C-8°C).
Do not freeze.
Keep the container in the outer carton in order to protect from light.
Shelf-Life: 3 (three) years.
J07CA09 - diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B ; Belongs to the class of combined bacterial and viral vaccines.
Vaccine (inj, pre-filled syringe + 2 separate needles) 0.5 mL x 1's.